GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Parenterals Ltd

Sai Parenterals Q2 FY27 Net Profit Rs. 105.10 Million; Acquires SP Analytics

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 01 Nov 2026, 02:52 PM IST  ·  BSE ID: 747bea0f-ff26-4a87-9071-e49edeca6156
View Original BSE Filing (PDF)
💡
In Simple Terms
Sai Parenterals announced its quarterly earnings, showing a net profit of Rs. 105.10 Million, and completed two subsidiary acquisitions.
🤖 AI Summary
  • Sai Parenterals Ltd. reported consolidated net profit of Rs. 105.10 Million for Q2 FY27, ended September 30, 2026.
  • Consolidated revenue from operations for Q2 FY27 stood at Rs. 1,940.18 Million.
  • The company will acquire the remaining 25% equity in SP Analytics Private Limited for Rs. 25,000/-, making it wholly owned.
  • Acquisition of 60% equity share capital of Saicriti Pharma Private Limited has been completed, making it a subsidiary.
  • A Management Committee was constituted for the smooth functioning and administration of the company.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations (Q2 FY27)
Rs. 1,940.18 Million
262.53%
Consolidated Net Profit After Tax (Q2 FY27)
Rs. 105.10 Million
65.51%
Basic EPS After Exceptional Items (Q2 FY27)
Rs. 2.38
395.83%
Cost of acquiring remaining 25% equity in SP Analytics
Rs. 25,000/-
🏢 How This Affects the Company
📈
Business Impact
The full acquisition of SP Analytics Private Limited and the completed acquisition of Saicriti Pharma Private Limited expands the company's control over its subsidiaries and strengthens its presence in the pharma sector, including testing and analysis.
💰
Financial Impact
The acquisitions introduce a subsidiary, Saicriti Pharma Private Limited, into the consolidated financials, and fully consolidate SP Analytics Private Limited, impacting future financial reporting. The total cost of acquiring the remaining 25% of SP Analytics is Rs. 25,000/-.
⚙️
Operational Impact
The constitution of a Management Committee aims to streamline internal processes and improve administrative efficiency within the company. Integrating newly acquired subsidiaries may require operational adjustments.
⚠️
Risk Impact
The acquisition of SP Analytics is a Related Party Transaction as the entity being acquired is a related party and promoter/promoter group has an interest. The company states the transaction is at arm's length based on agreed terms and assessment.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this board meeting outcome.
👤
Who Is Affected
All shareholders are affected by the company's financial performance (Q2 FY27 Net Profit Rs. 105.10 Million) and strategic decisions (acquisitions, management committee formation).
🔍
Management Signal
The management's decision to complete acquisitions and establish a Management Committee indicates a focus on consolidation, operational efficiency, and strategic expansion within the pharma sector.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — monitor consolidated revenue and profit growth.
Completion of SP Analytics acquisition — check for updates by 31.12.2026.
Integration of Saicriti Pharma — assess impact on future operational performance.
MEDIUM RISK Acquisition of a subsidiary with nil turnover in prior years may pose integration and profitability risks. Negative cash from operations is also a concern.
💡 Investor Takeaway
Sai Parenterals reported Q2 FY27 consolidated net profit of Rs. 105.10 Million and revenue from operations of Rs. 1,940.18 Million. The company completed the acquisition of 60% of Saicriti Pharma Private Limited and will acquire the remaining 25% of SP Analytics Private Limited for Rs. 25,000/-.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Net Profit After Tax for Q2 FY27 increased to Rs. 105.10 Million from Rs. 63.50 Million in Q2 FY26.
  • Consolidated Revenue from Operations for Q2 FY27 increased to Rs. 1,940.18 Million from Rs. 535.28 Million in Q2 FY26.

⚠️ Concerns

  • SP Analytics Private Limited, a subsidiary now being fully acquired, reported nil turnover during the last three financial years.
  • Cash Generated from Operations for the half year ended 30 September 2026 was negative (Rs. 2,012.98 Million).
📅 Company Track Record
Sai Parenterals Ltd. was recently listed with an IPO within the last 12 months. Limited public track record is available. The company requested an extension for Q3 FY26 results in April 2026 due to audit delays related to an acquired Australian subsidiary.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sai Parenterals Ltd.'s consolidated net profit for Q2 FY27?
Sai Parenterals Ltd.'s consolidated net profit after tax for the quarter ended September 30, 2026 (Q2 FY27) was Rs. 105.10 Million.
What was the revenue from operations for Sai Parenterals in Q2 FY27?
The consolidated revenue from operations for Sai Parenterals Ltd. in Q2 FY27 was Rs. 1,940.18 Million.
Which subsidiaries did Sai Parenterals Ltd. acquire?
Sai Parenterals Ltd. completed the acquisition of 60% of Saicriti Pharma Private Limited and will acquire the remaining 25% equity in M/s. SP Analytics Private Limited, making it a wholly owned subsidiary.
What is the cost of acquiring the remaining stake in SP Analytics Private Limited?
The cost of acquiring the remaining 25% equity shareholding in M/s. SP Analytics Private Limited is Rs. 25,000/- for 2,500 equity shares of face value Rs. 10/- each.
What is the indicative timeline for the completion of the SP Analytics Private Limited acquisition?
The indicative time period for completion of the acquisition of SP Analytics Private Limited is on or before December 31, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.